FAST is an all-volunteer organization of families and professionals dedicated to finding a cure for Angelman Syndrome and related disorders through the funding of an aggressive research agenda, education, and advocacy. The Foundation is committed to assisting individuals living with Angelman Syndrome to realize their full potential and quality of life.  Our goal is to bring practical treatment into current medical practice as quickly as possible. It is our hope that grants we fund will lead to additional research support from government agencies, other funding sources and organizations around the globe. FAST is served by two boards; the Board of Directors and the Scientific Advisory Board. Together, we are working hard to bring practical treatment into current medical practice as quickly as possible.

Our Priorities

We are 100% committed to accelerating treatments and a cure for Angelman Syndrome. The symptoms of Angelman Syndrome have been under addressed in the research community for far too long.  Research aimed at identifying treatments for the motor dysfunction, seizures and behavioral characteristics of Angelman Syndrome is one of FAST’s top priorities.  FAST takes pride in investing in high-risk, high-reward research grants that have already produced positive and promising results. A cure for Angelman Syndrome is now within reach but will require the expertise and collaboration of the best and brightest minds from a variety of fields in science and research.   A true research collaboration, and the infrastructure required to advance a cure for Angelman Syndrome, was non-existent.  FAST addressed this challenge by creating the first of its kind FIRE Initiative (FAST Integrative Research Environment) which funds twenty-four scientists, from four universities, to work collaboratively to identify, characterize and implement new therapeutics for the treatment and ultimate cure of Angelman Syndrome.  The FIRE Initiative is the most aggressive research program to date into finding a cure for Angelman Syndrome.

Transparency

The Foundation for Angelman Syndrome Therapeutics is an Internal Revenue Code Section 501(c)(3), a non-profit charity, exempt from federal taxation. Transparency is both a requirement and an obligation that is also vitally important to our members.

2015 – Below you will find a link to the Foundation for Angelman Syndrome Therapeutics’ (“FAST”) 2015 Audited Financial Statements as well as a link to the FAST 2015 Federal Tax Return.  The FAST calendar year ended 2015 audited financials show total revenue of $1,121,173 and total expenses of $1,348,143. Expenses of $1,348,143 include research funding in the amount of $1,116,067 and $125,910 in other program-related expenses.  Fundraising expenses totaled $82,549, and general administrative expenses incurred by FAST in 2015 were $23,617.  $1,194,959 of assets held at year-end are maintained in cash and investments, and they will be held until used for funding research towards a cure for Angelman Syndrome and advancing the goals of FAST. For detailed information, please see FAST 2015 Audited Financials and Federal Tax Return.

2014 – Below you will find a link to the Foundation for Angelman Syndrome Therapeutics’ (“FAST”) 2014 Audited Financial Statement as well as a link to the FAST 2014 Federal Tax Return.  The FAST calendar year ended 2014 audited financials show total revenue of $1,576,826 and total expenses of $1,256,386. Expenses of $1,256,386 include research funding in the amount of $1,042,667 and $112,293 in other program-related expenses.  Fundraising expenses totaled $78,121, and general administrative expenses incurred by FAST in 2014 were $23,305.  $1,571,929 of assets held at year-end are maintained in cash and investments, and they will be held until used for funding research towards a cure for Angelman Syndrome and advancing the goals of FAST.  For detailed information, please see FAST 2014 Audited Financials and Federal Tax Return.

2013 – Below you will find a link to the Foundation for Angelman Syndrome Therapeutics’ (“FAST”) 2013 Audited Financial Statement as well as a link to the FAST 2013 Federal Tax Return. The FAST calendar year ended 2013 audited financials show total revenue of $913,798 and total expenses of $979,548. Expenses of $979,548 include research funding in the amount of $808,469 and $63,544 in other program-related expenses. Total general administrative expenses incurred by FAST in 2013 were $24,509. $1,101,489 of assets held at year-end are maintained in cash and investments, and they will be held until used for funding research towards a cure for Angelman Syndrome and advancing the goals of FAST. For detailed information, please see FAST 2013 Audited Financials and Federal Tax Return 2013.

2012 – The FAST calendar year ended 2012 audited financials show total revenue of $955,052 and total expenses of $391,600. Expenses of $391,600 include research funding in the amount of $253,890 and $58,550 in other program-related expenses.  Total general administrative expenses incurred by FAST in 2012 were $34,920, which included $17,476 of general administrative expenses and temporarily restricted funds of $17,444 for family travel expenses incurred in the Minocycline Clinical Trial.  $1,167,239 of assets held at year-end are maintained in cash and investments, and they will be held until used for funding research towards a cure for Angelman Syndrome and advancing the goals of FAST. For further details visit the following hyperlinks; Audited Financial Statements 2012 & Federal Tax Return 2012.

2011 – The FAST calendar year ended 2011 audited financials show total revenue of $639,525 and total expenses of $207,400. Expenses of $207,400 include research funding in the amount of $125,110 and other program-related expenses of $41,561.  Total general administrative expenses incurred by FAST in 2011 were $6,621.  $603,787 of assets held at year-end are maintained in cash and investments, and they will be held until used for funding research towards a cure for Angelman Syndrome and advancing the goals of FAST. For further details visit the following hyperlinks; Audited Financial Statements 2011 & Federal Tax Return 2011.

 

View our Conflict of Interest & Whistleblower Policy

  • Why Fast Was Formed

    Chairperson and founder Paula Evans talks about why FAST was founded…Read More


    Leadership & Staff

    FAST is served by two boards who work together to bring practical treatments into current medical practice as quickly as possible.


    Roadmap to a Cure

    Read more about our strategy to bring safe and effective treatments to market as quickly as possible…Read More

Subscribe to our mailing list

* indicates required